Mineralocorticoid receptor antagonist - Wikipedia
A mineralocorticoid receptor antagonist (MRA or MCRA) [1] or aldosterone antagonist, is a diuretic drug which antagonizes the action of aldosterone at mineralocorticoid receptors. This group of drugs is often used as adjunctive therapy, in combination with other drugs, for the management of chronic heart failure.
List of Aldosterone receptor antagonists - Drugs.com
Aldosterone receptor antagonists (also called an antimineralocorticoid, MCRA, and sometimes MRA) are a class of drugs which block the effects of aldosterone. Aldosterone is the main mineralocorticoid hormone in the body and is produced in the adrenal cortex of the adrenal gland.
How Do Aldosterone Antagonists Work? - Cleveland Clinic
2022年4月29日 · Aldosterone antagonists (mineralocorticoid receptor antagonists) make your kidneys move extra water and salt into your pee so they’re out of your body. They do this while preventing you from losing potassium, which aldosterone makes your kidneys eliminate. They work by blocking the receptor for the hormone aldosterone, which your body makes.
Mineralocorticoid Antagonist - an overview - ScienceDirect
Mineralocorticoid receptor antagonists (MRAs, also referred to as aldosterone antagonists), are drugs that inhibit the action of aldosterone at the mineralocorticoid receptor on the adrenal cortex. From: Bioorganic & Medicinal Chemistry Letters, 2018.
Non-steroidal mineralocorticoid receptor antagonists (nsMRAs)
2023年5月15日 · Non-steroidal mineralocorticoid receptor antagonists (nsMRAs) like finerenone help protect kidneys and lower cardiovascular risk. Learn about their uses, effectiveness, and side effects.
Mineralocorticoid Receptor Antagonists: a Comprehensive …
2020年9月10日 · Recent findings: MRAs are well known for their utility in treating heart failure, refractory hypertension, and diverse nephropathies, namely, diabetic nephropathy. As their name denotes, MRAs inhibit the action of aldosterone at the mineralocorticoid receptor, preventing receptor activation.
Mineralocorticoid Receptor Antagonists - DrugBank Online
A nonsteroidal mineralocorticoid receptor antagonist indicated to lower the risk of eGFR decline, end stage kidney disease, cardiovascular death, heart attack, and hospitalization for heart failure in chronic kidney disease associated with type 2 diabetes.
Steroidal and non-steroidal mineralocorticoid receptor antagonists …
2020年10月25日 · Abstract. This review covers the last 80 years of remarkable progress in the development of mineralocorticoid receptor (MR) antagonists (MRAs) from synthesis of the first mineralocorticoid to trials of nonsteroidal MRAs. The MR is a nuclear receptor expressed in many tissues/cell types including the kidney, heart, immune cells, and fibroblasts.
30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid …
Abstract. The cDNA of the mineralocorticoid receptor (MR) was cloned 30 years ago, in 1987. At that time, spirolactone, the first generation of synthetic steroid-based MR antagonists (MRAs), which was identified in preclinical in vivo models, had already been in clinical use for 30 years. Subsequent decades of research and development by Searle & Co., Ciba-Geigy, Roussel …
Mineralocorticoid Antagonist - an overview | ScienceDirect Topics
A Mineralocorticoid Antagonist is a type of agent that works against the effects of aldosterone by blocking its action at mineralocorticoid receptors. These antagonists, such as spironolactone and eplerenone, are commonly used in the treatment of hypertension and heart failure.